Eye Disease Archives

spark therapeutics genable gene therapy blindness pigmentosa rhonova

News and Trends 8 Mar 2016

Irish Gene Therapy for Blindness is Acquired by US Leader in the Field

Spark Therapeutics (US) has paid over €13.5M for Genable Technologies (Ireland) and its gene therapy for a degenerative eye disease which progresses to blindness. Spark Therapeutics is one of the players in the re-emerging field of Gene Therapy (which is already establishing records like the most expensive drug). It focuses on debilitating genetic diseases, like inherited […]

March 8, 2016 - 3 minutesmins - By Denise Neves Gameiro

macular degeneration xbrane helvetic xlucane biosimilar lucentis blindness iran

News and Trends 18 Jan 2016

Where there be Patent-Free Markets: Swiss-Swedish Biosimilar for Blindess Reaches Iran

Helvetic BioPharma (Switzerland) estimates that 70,000 people suffer from age-related macular degeneration in Iran, the leading cause of blindness. This deal with Xbrane in Stockholm (Sweden) will debut a biosimilar therapy that could really tackle this problem. Xbrane itself is a Swedish biopharma with links to Italy (after an acquisition of the Italian Primm Pharma […]

January 18, 2016 - 2 minutesmins - By Dani Bancroft

crispr bayer therapeutics genetic disease joint venture london

News and Trends 22 Dec 2015

Serious Genetic Diseases have a New CRISPR Dream Duo Venture worth in Excess of €275M

Blood disorders, blindness and congenital heart disease? The new Bayer Life Science Center (BLSC) in Germany and CRISPR Therapeutics (Switzerland) have now created a joint Venture to tackle cures for these rare genetic defects. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise […]

December 22, 2015 - 2 minutesmins - By Dani Bancroft

nightstarx oxford chroideremia night blindness

News and Trends 11 Nov 2015

Oxford’s Nightstar Gene Therapy for Blindness in Men Shines with $35M Fundraiser

Choroideremia is a rare X-linked recessive retinal disease which eventually leads to blindness. A series B funding round has landed the NightstaRx (‘Nightstar’) biotech in Oxford an additional $35M for their vision-improving gene therapy. Since the mutation causing Choroideremia is sex-linked, sufferers are almost always males, with the onset of symptoms in childhood often starting […]

November 11, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 30 Sep 2015

Apitope relocates to Wales after €12M series B financing round

Now, as we’ve recently discussed here at Labiotech, there doesn’t appear to be many Welsh biotechs…however, this is all about to change, with major Autoimmune disease focused Apitope relocating it’s HQ to Wales. This is following a €12M series B fundraiser led by the Wales Lifesciences Fund for its monoclonal antibody pipeline. Aptiope are currently […]

September 30, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 14 Sep 2015

Leading Cause of blindness has new US & EU Orphan Drug Designation Immunotherapy

TxCell, from Nice (Fr), has been granted EU and US Orphan Drug Designation for its T-cell based therapy for autoimmune uveitis – an eye inflammatory disease responsible of 10-15% legal blindness in developed countries. TxCell is a spin-off from France’s National Institute for Health and Medical Research (Inserm), with a pipeline including a phase II […]

September 14, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 26 Aug 2015

Oh dear, Allergan is doing its 4th product recall in 2015 …

Allergan is fighting with manufacturing problems – again! The packaging of some eye treating products were defective and contaminated the eye ointments. Due to safety concerns, these products are recalled by the Irish company. Customers were complaining that when unscrewing the cap from the aluminum tube of the eye oinments, particles from the cap were […]

August 26, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 6 Aug 2015

Aging-diseases expert Biophytis launches its IPO in Paris

[Update August 6th, 2015] A month after its Initial Public Offering in Paris, Biophytis just announced that the company raised an extra €6 million from a North-American investor. This fresh money is joining the €10 million successfully raised by the French biotech on July 8th, 2015. Original article published on June 26th, 2015: The Parisian biotech Biophytis […]

August 6, 2015 - 2 minutesmins - By Lourdes Riquelme

eye Bayer Healthcare Johns Hopkins University

News and Trends 9 Jul 2015

Vision specialist Gensight eyes a €90M IPO on NASDAQ

French Gensight intends to raise one of the biggest European IPOs on the American stock market. The gene-therapy specialist will pursue €90.6M to advance with two early-stage candidates for orphan eyes diseases. Gensight will travel across the Ocean to look for the same success its compatriots had on the American stock market. The company will […]

July 9, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 16 Jun 2015

Bayer set a strategic alliance with J. Hopkins in retinal diseases

Bayer HealthCare and the Johns Hopkins University in Baltimore have entered into a five-year collaboration to develop ophthalmic therapies. The partners will jointly work on the discovery of treatments of retinal diseases such as age-related macular degeneration. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory […]

June 16, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 3 Feb 2015

AYOXXA raises its sights with a new agreement to develop ophthalmic diagnostic tools

New agreement was signed between AYOXXA, an international biotech company with headquarters in Cologne, and the Singapore Eye Research Institute (SERI), one of the leading international eye research institutes. AYOXXA and SERI will work together on validating the company’s multiplexing technology platform for protein biomarker detection, as part of an expanded collaboration for developing ophthalmic […]

February 3, 2015 - 3 minutesmins - By Lourdes Riquelme

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us